PRLD (STOCKS)
Prelude Therapeutics Incorporated
$2.230000
+0.140000 (+6.70%)
Prev close: $2.090000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Krishna Vaddi
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $126.54M
- Employees
- 131
- P/E (TTM)
- -1.39
- P/B (TTM)
- 2.17
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.26 | $-0.37 | +0.1126 | +30.22% |
|
Jun 2025 (Q2)
|
$-0.41 | $-0.45 | +0.0383 | +8.54% |
|
Mar 2025 (Q1)
|
$-0.42 | $-0.48 | +0.0577 | +12.08% |
|
Dec 2024 (Q4)
|
$-0.38 | $-0.47 | +0.0926 | +19.59% |
Financial Statements
| Revenues | $10.50M |
| Benefits Costs and Expenses | $122.27M |
| Costs And Expenses | $122.27M |
| Operating Expenses | $131.55M |
| Research and Development | $107.93M |
| Other Operating Expenses | $23.62M |
| Operating Income/Loss | -$121.05M |
| Income/Loss From Continuing Operations After Tax | -$111.77M |
| Income/Loss From Continuing Operations Before Tax | -$85.55M |
| Net Income/Loss | -$111.77M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$111.77M |
| Net Income/Loss Available To Common Stockholders, Basic | -$111.77M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.47 |
| Diluted Earnings Per Share | -$1.47 |
| Basic Average Shares | 152,143,407 |
| Diluted Average Shares | 152,143,407 |
| Assets | $94.76M |
| Current Assets | $58.33M |
| Noncurrent Assets | $36.43M |
| Fixed Assets | $5.53M |
| Other Non-current Assets | $30.89M |
| Liabilities | $36.22M |
| Current Liabilities | $18.19M |
| Accounts Payable | $2.53M |
| Wages | $6.49M |
| Other Current Liabilities | $9.17M |
| Noncurrent Liabilities | $18.03M |
| Equity | $58.53M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $58.53M |
| Liabilities And Equity | $94.76M |
| Net Cash Flow From Operating Activities | -$100.17M |
| Net Cash Flow From Operating Activities, Continuing | -$100.17M |
| Net Cash Flow From Investing Activities | $135.92M |
| Net Cash Flow From Investing Activities, Continuing | $135.92M |
| Net Cash Flow From Financing Activities | -$162.00K |
| Net Cash Flow From Financing Activities, Continuing | -$162.00K |
| Net Cash Flow | $35.59M |
| Net Cash Flow, Continuing | $35.59M |
| Comprehensive Income/Loss | -$111.90M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$111.94M |
| Other Comprehensive Income/Loss | -$19.85M |